Nuvectis Pharma, Inc. (NVCT) Discusses Strategic In-Licensing Deal and Expansion Into Complement-Mediated Diseases and Oncology Prepared Remarks Transcript

Operator

Greetings, and welcome to the Nuvectis Pharma Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It’s now my pleasure to turn the call over to Ron Bentsur, Chairman and CEO of Nuvectis Pharma. Sir, please go ahead.

Ron Bentsur
Co-Founder, Chairman, CEO & President

Thank you very much. Good morning to everyone joining our call today. Following our safe harbor statement, I will review the details of the strategic in-licensing deal that we announced earlier this morning. Before we begin, I’d like to remind everyone on this call, we’ll be making forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements within the meaning of the federal securities laws are subject to substantial risks and uncertainties.

During this call, all statements other than statements of historical fact are considered forward-looking statements and are based on our interpretations of past events as well as current expectations, estimates and projections about future events. These and other risks and uncertainties are subject to market and other conditions and are described more fully in the section titled Risk Factors in our Form 10-Q for the quarter ended March 31, 2026, and our other public filings with the Securities and Exchange Commission. However, these risks are not exhaustive and new risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements made in this call or on other filings made with the SEC.

Now for the reason we’re having the call today. Today